Enveric Biosciences Inc Stock Price, News & Analysis

Enveric Biosciences (NASDAQ: ENVB) received a Notice of Allowance from the USPTO on November 26, 2025 for a U.S. patent application covering its EVM401 Series of molecules.

The allowed application, entitled "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives," will be the fourth U.S. patent for the EVM401 program and is described as broadening claims to additional potential non-hallucinogenic neuroplastogenic molecules aimed at neuropsychiatric and addiction disorders. The company said the allowance, once issued as a patent, expands its intellectual property estate and strengthens its pipeline of next-generation, non-hallucinogenic neuroplastogens.

Enveric Biosciences (NASDAQ: ENVB) reported Q3 2025 results and operational progress toward an IND for lead candidate EB-003. Key clinical and CMC milestones include completion of pre-IND dose range finding studies establishing a maximum tolerated dose, positive preclinical PTSD model data (significant reduction in context-induced freezing, p < 0.05), receipt of an FDA written response to a pre-IND meeting request, and production of a 1-kilogram pharmaceutically compatible salt batch to support IND-enabling work.

Corporate actions: issued and pursued patents, hired outside counsel to defend U.S. Patent No. 12,138,276, relocated headquarters to Cambridge, MA, completed warrant exercises generating approximately $2.2 million gross, completed a reverse 1-for-12 stock split after a Nasdaq bid-price deficiency, and reported Q3 net loss of $3.4 million with $3.8 million cash as of September 30, 2025.

Enveric Biosciences (NASDAQ: ENVB) will effect a 1-for-12 reverse stock split, effective at 8:00 a.m. New York time on October 28, 2025. The company received a Nasdaq delisting determination on October 22, 2025 related to minimum bid price, and the Board approved the 1-for-12 ratio under a previously authorized 1-for-5 to 1-for-50 range.

The reverse split will convert every 12 pre-split shares into one post-split share, reduce outstanding common stock from 6,219,568 to approximately 518,297 shares, and apply proportional adjustments to equity awards and warrants. Fractional shares will be rounded up to whole shares.

Enveric Biosciences (NASDAQ: ENVB) announced issuance of its 23rd U.S. patent from the USPTO, U.S. Patent No. 12,428,408, titled “Fused Heterocyclic Mescaline Derivatives.”

The patent covers a unique series of neuroplastogenic small-molecule compounds designed to target key serotonin receptors and promote neuroplasticity, expanding Enveric’s intellectual property footprint and supporting potential pipeline expansion for treatments of psychiatric and neurological disorders.

Enveric Biosciences (NASDAQ: ENVB) said it retained Fish and Richardson to defend U.S. Patent No. 12,138,276 (the ‘276 patent) after a Post‑Grant Review petition was filed by Gilgamesh Pharmaceuticals on claims that appear relevant to Bretisilocin (GM‑2505), which AbbVie agreed to acquire on August 25, 2025 in a definitive transaction valued at up to $1.2 billion. The ‘276 family includes one issued U.S. patent, additional pending U.S. and international applications, and is separate from Enveric’s EB‑003 patent families.

Enveric reported an intellectual property portfolio of 26 issued U.S. patents and 60 pending national and international applications, multiple programs advancing toward clinical development, and out‑license agreements with potential aggregate milestones of up to $205 million plus royalties.

Enveric Biosciences (NASDAQ: ENVB) announced on October 14, 2025 that its Board authorized the Capital Markets Committee to explore and negotiate non-binding term sheets for potential Digital Asset Treasury (DAT) strategy opportunities.

Any DAT opportunities would require further review and approval by the full Board. The company said this initiative is intended to enhance shareholder value and support long-term growth while it remains committed to advancing its core biotechnology programs. The company will provide updates as developments occur.

Enveric Biosciences (NASDAQ: ENVB) has achieved significant chemistry, manufacturing, and controls (CMC) milestones for its lead candidate EB-003, advancing towards first-in-human clinical trials. The company has successfully: produced a pharmaceutically compatible salt form, developed a scalable synthetic route, and manufactured a 1-kilogram batch of EB-003.

EB-003 is a novel small molecule with dual agonism at 5-HT1B and 5-HT2A receptors, targeting neuropsychiatric conditions. These manufacturing achievements are crucial for supporting upcoming Investigational New Drug (IND) application activities, including GLP toxicology studies and drug product formulation work.

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on neuroplastogenic small molecules, has announced the closing of previously announced warrant exercises, generating $2.2 million in gross proceeds. The transaction involved the exercise of series A and B warrants at a reduced price of $0.915 per share, down from the original $3.00 per share.

In exchange for the immediate cash exercise, Enveric issued new unregistered warrants: Series C warrants for up to 2,424,998 shares (5-year term) and Series D warrants for up to 2,424,998 shares (18-month term), both with a $0.915 exercise price. The company plans to use proceeds for product development, working capital, and general corporate purposes.

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on neuroplastogenic small molecules, has announced warrant exercises that will generate $2.2 million in gross proceeds. The company secured agreements for the immediate exercise of series A and B warrants totaling 2,424,998 shares at a reduced price of $0.915 per share, down from the original $3.00 exercise price.

In exchange for the immediate cash exercise, Enveric will issue new unregistered series C and D warrants, each allowing the purchase of up to 2,424,998 shares at $0.915 per share. The series C warrants will have a 5-year term, while series D warrants will expire in 18 months. The company plans to use the proceeds for product development, working capital, and general corporate purposes.